Iron Deficiency Anemia in Children: Comprehensive Pathophysiological Insights, Diagnostic Evolution
1. Jamali Mohd Javed
2. Osmonova Gulnaz Zhenishbaevna
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Iron deficiency anemia (IDA) in the pediatric population remains one of the most prevalent and impactful nutritional disorders worldwide, threatening physical growth, immune competence, and cognitive development. The pathogenesis is fundamentally rooted in an imbalance between systemic iron requirements and physiological iron availability, which is further modulated by the master iron-regulatory peptide hormone hepcidin in response to nutritional deficits, accelerated somatic growth spurts, or chronic inflammatory conditions. Recent clinical updates emphasize proactive risk-based screening strategies, refined serum ferritin diagnostic thresholds, and careful differentiation between uncomplicated nutritional iron deficiency and complex gastrointestinal or genetic disorders. Contemporary management centers around optimized oral iron regimens, innovative alternative formulations, and the judicious incorporation of parenteral iron therapy for refractory cases. This review provides a comprehensive synthesis of current pathophysiological discoveries, updated diagnostic criteria, and modern evidence-based therapeutic frameworks for managing pediatric iron deficiency anemia.
Introduction
Iron deficiency anemia in infants, children, and adolescents represents a global health challenge with profound short- and long-term consequences. Iron is an indispensable micronutrient required for numerous fundamental biological processes, including oxygen transport via hemoglobin, cellular respiration, energy metabolism, and optimal neurodevelopment during critical windows of structural brain maturation. In the pediatric population, vulnerability to iron depletion is particularly high due to rapid rates of somatic growth and expansion of red cell mass, which place extraordinary demands on total body iron reserves. Despite widespread nutritional fortification programs and public health campaigns, childhood iron deficiency persists at unacceptably high rates across both developing and developed nations, frequently clustering among vulnerable socioeconomic groups, premature infants, and adolescents experiencing heavy menstrual bleeding.
Historically, the clinical approach to pediatric iron deficiency anemia relied heavily on reactive testing and standardized high-dose daily oral iron regimens that frequently provoked gastrointestinal intolerance and poor adherence. Over the last decade, advances in molecular physiology have elucidated the pivotal regulatory role of hepcidin and inflammatory pathways, prompting a re-evaluation of diagnostic thresholds and dosing schedules. Recent consensus guidelines from major pediatric and hematologic societies have updated screening protocols and therapeutic standards to optimize clinical outcomes while minimizing adverse drug events. This article provides an extensive, multi-dimensional evaluation of the pathophysiology, clinical presentation, diagnostic evaluation, and modern management strategies governing iron deficiency anemia in pediatric cohorts.
Materials and Methods
To construct a comprehensive, university-grade medical manuscript structured in accordance with the standard IMRAD format, an exhaustive literature review was conducted across prominent biomedical databases, including PubMed, MEDLINE, and the Cochrane Library. Literature searches prioritized articles published between 2012 and 2026, focusing specifically on pediatric iron deficiency anemia, systemic iron homeostasis, hepcidin regulation, international consensus screening guidelines, and contemporary clinical trials evaluating oral and intravenous iron therapies. Selection criteria favored randomized controlled trials, multicenter cohort analyses, systematic reviews, and updated clinical practice reports published by pediatric hematology consortia and international health authorities. Sources were critically appraised for methodological rigor, sample size, and clinical applicability to pediatric populations, resulting in the integration of key peer-reviewed studies and authoritative guidelines to substantiate the findings presented herein.
Results
Pathophysiology and Systemic Iron Homeostasis
The systemic regulation of iron balance in children is tightly controlled to prevent both the toxic accumulation of excess free iron and the debilitating consequences of deficiency. Because humans lack an active physiological excretory pathway for iron, systemic homeostasis is maintained entirely at the level of intestinal absorption and reticuloendothelial recycling. Dietary iron exists primarily in two forms: heme iron, which is efficiently absorbed via specialized enterocyte transporters, and non-heme iron, which requires reduction at the brush border before uptake via divalent metal transporter 1. Once absorbed across the duodenal enterocyte, iron is exported into the circulation by ferroportin and subsequently bound to transferrin for systemic delivery to erythroid bone marrow and other tissues.
The master regulator of this intricate pathway is hepcidin, a small peptide hormone synthesized primarily by hepatocytes. Hepcidin binds directly to ferroportin, inducing its internalization and lysosomal degradation, thereby trapping iron within enterocytes, macrophages, and hepatic stores. In pediatric iron deficiency, depleted iron stores and accelerated erythropoietic drive suppress hepatic hepcidin synthesis, upregulating ferroportin expression to maximize intestinal iron absorption and enhance iron recycling from the reticuloendothelial system. Conversely, in the presence of acute or chronic inflammation, pro-inflammatory cytokines such as interleukin-6 stimulate hepcidin production, shutting down iron export and precipitating the functional iron deficiency characteristic of chronic disease states. When total body iron stores become exhausted and circulating iron is insufficient to meet the demands of erythropoiesis, iron deficiency anemia ensues, marked by microcytic, hypochromic erythrocytes and impaired cellular energetics.
Clinical Presentation and Diagnostic Evaluation
The clinical presentation of pediatric iron deficiency anemia varies widely depending on the rate of onset, severity of the deficit, and the developmental stage of the child. Infants and toddlers with mild to moderate iron deficiency may remain entirely asymptomatic or exhibit subtle manifestations such as irritability, apathy, reduced attentiveness, and impaired motor development. Older children and adolescents frequently report generalized fatigue, exercise intolerance, pallor, dizziness, and headache. In severe or chronic cases, patients may develop behavioral disturbances and pica—the compulsive ingestion of non-nutritive substances such as ice, clay, starch, or paper. Physical examination findings in advanced iron deficiency can reveal koilonychia, angular cheilitis, glossitis, tachycardia, and systolic flow murmurs indicative of hyperdynamic circulation secondary to profound anemia.
Establishing an accurate diagnosis requires a comprehensive laboratory evaluation interpreted within the clinical context of the patient. The initial diagnostic workup centers on a complete blood count paired with a careful manual review of the peripheral blood smear. The hallmark hematologic findings include microcytosis, reflected by a reduced mean corpuscular volume, and hypochromia, accompanied by an increased red cell distribution width that highlights anisocytosis. To confirm iron deficiency, serum ferritin serves as the primary biochemical marker reflecting total body iron stores, with updated consensus guidelines establishing reduced thresholds—such as serum ferritin below 20 ng/mL for young and school-aged children—to reliably identify depleted reserves. However, clinicians must maintain vigilance regarding the confounding influence of acute-phase responses, as ferritin is an acute-phase reactant that can be spuriously elevated into the normal range during concurrent infections, inflammatory disorders, or systemic illnesses. In such inflammatory scenarios, supplementary markers such as transferrin saturation, soluble transferrin receptor assays, or reticulocyte hemoglobin content provide valuable complementary diagnostic insight.
Contemporary Therapeutic Paradigms and Management Strategies
The modern therapeutic management of pediatric iron deficiency anemia focuses on restoring normal hemoglobin levels, aggressively replenishing depleted iron stores, and identifying and treating the underlying root cause of the deficiency. For uncomplicated nutritional iron deficiency, standard management centers on dietary counseling and oral iron supplementation. Dietary interventions emphasize the elimination of excessive cow's milk intake—which can cause occult gastrointestinal micro-hemorrhages and inhibit iron absorption—alongside the introduction of iron-rich complementary foods and vitamin C-rich enhancers to boost non-heme iron bioavailability.
Oral iron supplementation traditionally utilized daily elemental iron dosing regimens, such as ferrous sulfate administered at 3 mg/kg to 6 mg/kg daily. However, recent clinical investigations highlight the advantages of alternative dosing schedules, such as alternate-day oral iron administration, which optimizes fractional iron absorption by preventing the hepcidin spikes induced by daily dosing, thereby significantly improving gastrointestinal tolerance and adherence. For children experiencing persistent gastrointestinal distress, poor palatability, or mild malabsorption associated with conditions like inflammatory bowel disease or celiac disease, modern alternative oral formulations—such as iron amino acid chelates, liposomal iron, and sucrosomial ferric pyrophosphate—offer excellent efficacy with markedly reduced adverse side effect profiles.
For patients who fail oral iron therapy due to refractory malabsorption, ongoing unmanageable gastrointestinal blood loss, or severe systemic complications requiring rapid repletion, intravenous iron administration represents a transformative therapeutic advancement. Modern parenteral iron formulations, such as ferric carboxymaltose and iron isomaltoside, allow for the safe administration of large single-dose infusions in outpatient settings, rapidly correcting hemoglobin deficits and replenishing storage pools without the severe hypersensitivity reactions historically associated with older dextran-based products. Meticulous longitudinal follow-up, including repeat complete blood counts and ferritin assessments scheduled at one and three months following the initiation of therapy, ensures sustained hematologic recovery and successful repletion of systemic iron stores.
Discussion
The clinical understanding and management of iron deficiency anemia in children have undergone profound refinements over the past decade, shifting toward more individualized, physiology-driven care pathways. A central theme emerging from contemporary pediatric hematology literature is the critical recognition that iron deficiency exerts detrimental neurodevelopmental impacts even before frank anemia manifests. Consequently, updated clinical guidelines emphasize proactive, risk-based screening programs targeting vulnerable populations, including premature infants, exclusively breastfed infants beyond six months of age without iron supplementation, toddlers consuming excessive unfortified cow's milk, and adolescents experiencing heavy menstrual bleeding or participating in high-endurance athletics. Early identification allows clinicians to intervene during reversible stages, preventing long-term cognitive and behavioral deficits that can impair academic potential and quality of life.
Another pivotal advancement involves the optimization of therapeutic delivery mechanisms to overcome the historical barriers of gastrointestinal intolerance and poor adherence that plagued traditional daily high-dose oral iron regimens. The growing body of evidence supporting alternate-day dosing schedules and novel bioavailable formulations, such as liposomal and sucrosomial iron, represents a major clinical victory for pediatric patients and their caregivers. By minimizing adverse effects like abdominal cramping, nausea, and tooth discoloration, these strategies foster higher adherence rates and therapeutic success. Furthermore, the expansion of safe, rapid-infusion parenteral iron preparations has revolutionized the care of children with complex underlying gastrointestinal disorders, such as inflammatory bowel disease, where ongoing mucosal inflammation and elevated hepcidin levels render oral iron therapy ineffective.
Despite these notable advances, significant clinical challenges remain in global public health and underserved communities, where nutritional deficiencies are inextricably linked to poverty, food insecurity, and infectious disease burdens. Future research priorities must focus on refining point-of-care diagnostic tools to accurately assess iron status in inflammatory settings, evaluating long-term neurodevelopmental outcomes following early intervention, and harmonizing public health fortification strategies across international borders. Through continued collaboration among pediatricians, hematologists, and public health authorities, the medical community can systematically dismantle the barriers of iron deficiency and safeguard the health of future generations.
Conclusion
Iron deficiency anemia in children is a multifaceted nutritional and systemic disorder that poses profound threats to pediatric growth, immunity, and neurodevelopment. Driven by imbalances between physiological demand and supply, the condition is centrally regulated by hepcidin and inflammatory pathways that dictate systemic iron availability. Modern diagnostic frameworks emphasize proactive screening in high-risk pediatric groups, careful interpretation of serum ferritin amidst acute-phase reactants, and the systematic exclusion of underlying gastrointestinal or genetic pathologies. Therapeutic management has successfully transitioned toward patient-tailored oral regimens utilizing optimized dosing schedules and advanced bioavailable formulations, supplemented by the judicious use of modern intravenous iron infusions for refractory cases. Through rigorous adherence to evidence-based guidelines and comprehensive multi-disciplinary care, iron deficiency anemia can be effectively prevented, diagnosed, and cured, ensuring optimal developmental trajectories for affected children.
References
1. Powers, J. M. (2026). Prevention, Screening, Diagnosis, and Treatment of Iron Deficiency and Iron Deficiency Anemia in Infants, Children, and Adolescents: Clinical Report. Pediatrics, 158(1), e2026077414. https://doi.org/10.1542/peds.2026-077414 Cited by: 5
2. Leone, G., et al. (2026). Iron Therapy in Pediatric Iron Deficiency and Iron-Deficiency Anemia. Hematology Reports, 18(1), 6. https://doi.org/10.3390/hematolrep18010006 Cited by: 3
3. Powers, J. M. (2026). Prevention, screening, diagnosis, and treatment of iron deficiency and iron deficiency anemia in infants, children, and adolescents: Clinical report. Pediatrics, 158(1), e2026077414. https://doi.org/10.1542/peds.2026-077414 Cited by: 5
4. Rehman, T., Agrawal, R., Ahamed, F., Das, S., Mitra, S., Kumar, D., Sethy, C., Kanungo, S., Bhattacharya, D., & Pati, S. (2025). Optimal dose and duration of iron supplementation for treating iron deficiency anaemia in children and adolescents: A systematic review and meta-analysis. PLOS ONE, 20(2), e0319068. https://doi.org/10.1371/journal.pone.0319068 Cited by: 25
5. Chaber, R., Helwich, E., Lauterbach, R., Mastalerz-Migas, A., Matysiak, M., Peregud-Pogorzelski, J., Styczyński, J., Szczepański, T., & Jackowska, T. (2024). Diagnosis and treatment of iron deficiency and iron deficiency anemia in children and adolescents: Recommendations of the Polish Pediatric Society, the Polish Society of Pediatric Oncology and Hematology, the Polish Society of Neonatology, and the Polish Society of Family Medicine. Nutrients, 16(21), 3623. https://doi.org/10.3390/nu16213623 Cited by: 40
6. Leung, A. K. C., Lam, J. M., Wong, A. H. C., Hon, K. L., & Li, X. (2024). Iron deficiency anemia: An updated review. Current Pediatric Reviews, 20(3), 339–356. https://doi.org/10.2174/1573396320666230727102042 Cited by: 217
7. McEvoy, M. T., Stuckert, A. J., Castellanos, M. I., Gilbert, M. M., Pfeiffer, T., Prudowsky, Z., Rios, X., Airewele, G., Okcu, M. F., & Powers, J. M. (2022). Management of nutritional iron deficiency anemia for young children in the emergency department. Pediatric Blood & Cancer, 70(3), e30181. https://doi.org/10.1002/pbc.30181 Cited by: 13
8. Stoffel, N. U., Cercamondi, C. I., Brittenham, G., Moretti, D., Hurrell, R. F., & Zimmermann, M. B. (2017). Iron absorption from oral iron supplements given on consecutive days versus alternate days in iron-depleted women: A randomized controlled trial. The Lancet Haematology, 4(11), e524–e533. https://doi.org/10.1016/s2352-3026(17)30182-5 Cited by: 480
9. Camaschella, C. (2015). Iron deficiency. The New England Journal of Medicine, 372(19), 1832–1843. https://doi.org/10.1056/nejmra1401038 Cited by: 2850
10. Ganz, T., & Nemeth, E. (2012). Hepcidin and iron homeostasis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1823(9), 1434–1443. https://doi.org/10.1016/j.bbamcr.2012.01.020 Cited by: 1720
11. Domellöf, M., Braegger, C., Campoy, C., Colomb, V., Decsi, T., Fewtrell, M., Hojsak, I., Mihatsch, W., Molgaard, C., Shamir, R., Turck, D., & van Goudoever, J. B. (2014). Iron requirements of infants and young children. Journal of Pediatric Gastroenterology and Nutrition, 58(1), 119–129. https://doi.org/10.1097/mpg.0000000000000206 Cited by: 390
12. Lonnerdal, B. (2017). Excess iron intake as a factor in the development of iron deficiency anemia in children. The American Journal of Clinical Nutrition, 106(Suppl 6), 1618S–1623S. https://doi.org/10.3945/ajcn.117.155713 Cited by: 145
13. Pasricha, S. R., Tye-Din, J., Muckenthaler, M. U., & Swinkels, D. W. (2021). Iron deficiency. The Lancet, 397(10270), 233–248. https://doi.org/10.1016/s0140-6736(20)32594-0 Cited by: 920